Rallybio

Rallybio Corporation (NASDAQ RLYB) is a clinical-stage biotechnology company headquartered in New Haven, Connecticut, founded in 2018, developing and commercializing life-transforming therapies for patients with severe and rare diseases. Its pipeline spans maternal-fetal health, complement dysregulation, hematology, and metabolic disorders, led by RLYB116, a differentiated complement component 5 (C5) inhibitor, and RLYB332, a long-acting matriptase-2 (MTP-2) antibody for iron-overload disorders. The company was surfaced as a portfolio company of Canaan Partners and added to the API Evangelist network. As a pharmaceutical company it publishes no public developer API, SDK, or machine-readable API surface; this profile captures corporate identity only.

Rallybio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Rare Diseases, and Healthcare.

Rallybio’s developer surface includes engineering blog, support, and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub
13.0/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyPharmaceuticalsRare DiseasesHealthcareLife SciencesClinical Stage

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 13.0/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 1.3 / 20
Commercial Clarity 4.2 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/rallybio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Operate 1

Status, limits, changes, and where to get help

Support
Support

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService
TermsOfService
 PrivacyPolicy
PrivacyPolicy

Company 3

The organization behind the API

Website
Website
 About
About
 Blog
Blog

Source (apis.yml)

apis.yml Raw ↑ 
aid: rallybio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/rallybio.png
name: Rallybio
description: Rallybio Corporation (NASDAQ RLYB) is a clinical-stage biotechnology company headquartered in New Haven, Connecticut,
  founded in 2018, developing and commercializing life-transforming therapies for patients with severe and rare diseases.
  Its pipeline spans maternal-fetal health, complement dysregulation, hematology, and metabolic disorders, led by RLYB116,
  a differentiated complement component 5 (C5) inhibitor, and RLYB332, a long-acting matriptase-2 (MTP-2) antibody for iron-overload
  disorders. The company was surfaced as a portfolio company of Canaan Partners and added to the API Evangelist network. As
  a pharmaceutical company it publishes no public developer API, SDK, or machine-readable API surface; this profile captures
  corporate identity only.
url: https://raw.githubusercontent.com/api-evangelist/rallybio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Rare Diseases
- Healthcare
- Life Sciences
- Clinical Stage
apis: []
common:
- type: Website
  url: https://rallybio.com/
- type: About
  url: https://rallybio.com/about-us/
- type: Blog
  url: https://investors.rallybio.com/news-releases
- type: Support
  url: https://rallybio.com/contact/
- type: TermsOfService
  url: https://rallybio.com/terms-of-use/
- type: PrivacyPolicy
  url: https://rallybio.com/privacy-policy/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 0
  pass: local-v1